DALFAMPRIDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H6N2
Molecular Weight	94.1145
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=CC=NC=C1

InChI

InChIKey=NUKYPUAOHBNCPY-UHFFFAOYSA-N

InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022250s013lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.drugs.com/cdi/dalfampridine.html | https://clinicaltrials.gov/ct2/show/NCT01356940 | https://www.ncbi.nlm.nih.gov/pubmed/22497693 | https://www.ncbi.nlm.nih.gov/pubmed/15084131

Dalfampridine is a potassium channel blocker, used as a research tool in characterizing subtypes of the potassium channel. Dalfampridine has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptomatic improvement of walking in adults with several variations of the disease. The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated potassium channel subunit Kv1.3 8 Target ID: CHEMBL4633 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15084131	Blocker 537		195.0 µM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Multiple sclerosis 104 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022250s013lbl.pdf	Primary		Approved 8429	AMPYRA Approved Use AMPYRA (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) Launch Date 1.2641184E12

C_max

Value	Dose	Co-administered	Analyte	Population
23.77 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22058101/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		DALFAMPRIDINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
246.48 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22058101/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		DALFAMPRIDINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22058101/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		DALFAMPRIDINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
97% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22058101/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		DALFAMPRIDINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25583832 Page: p.3	unhealthy, 52.1 ± 8.8 n = 269 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 52.1 ± 8.8 Sex: M+F Population Size: 269 Sources: https://pubmed.ncbi.nlm.nih.gov/25583832 Page: p.3	Disc. AE: Seizure, Myocardial infarction... AEs leading to discontinuation/dose reduction: Seizure (1.1%) Myocardial infarction (1.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/25583832 Page: p.3
300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3	unhealthy n = 1 Health Status: unhealthy Condition: Multiple sclerosis Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3	Disc. AE: Weakness, Consciousness decreased... AEs leading to discontinuation/dose reduction: Weakness Consciousness decreased Memory loss Hypophonia Structural brain disorders NEC Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3
40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3	unhealthy n = 1 Health Status: unhealthy Condition: Multiple sclerosis Sex: F Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3	Disc. AE: Complex partial seizures, Confusion... AEs leading to discontinuation/dose reduction: Complex partial seizures Confusion Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3
60 mg single, oral Overdose Dose: 60 mg Route: oral Route: single Dose: 60 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3	unhealthy n = 1 Health Status: unhealthy Condition: Multiple sclerosis Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3	Disc. AE: Mental state abnormal... AEs leading to discontinuation/dose reduction: Mental state abnormal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.3
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.2	unhealthy n = 400 Health Status: unhealthy Condition: Multiple sclerosis Population Size: 400 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.2	Disc. AE: Headache, Balance disorder... AEs leading to discontinuation/dose reduction: Headache (0.5%) Balance disorder (0.5%) Dizziness (0.5%) Confusional state (0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.2
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Multiple sclerosis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.1	Disc. AE: Seizures... AEs leading to discontinuation/dose reduction: Seizures Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf Page: p.1

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	substrate 1037 inhibitor 1767 inducer 389	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Kv1.3 17 Kv1.5 26 CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP3A4/5 278 P-gp 1461	CYP1B1 92 CYP1A2 1054 P-gp 1537 CYP2E1 667 CYP1A1 349 CYP2B6 664 CYP2C8 693 CYP2C18 138 CYP2C19 991 CYP3A5 395 CYP4A11 119	CYP1A2 701 CYP2B6 547 CYP2C19 293 CYP2E1 128 CYP3A4/5 124

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28 Page: 41, (ClinPharm) 28, 50	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=50 Page: 41, (ClinPharm) 28, 50	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=50 Page: 41, (ClinPharm) 28, 50	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28 Page: 41, (ClinPharm) 28, 50	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=50 Page: 41, (ClinPharm) 28, 50	no
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28 Page: 41, (ClinPharm) 28, 50	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=50 Page: 41, (ClinPharm) 28, 50	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=50 Page: 41, (ClinPharm) 28, 50	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28 Page: 41, (ClinPharm) 28, 50	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=50 Page: 41, (ClinPharm) 28, 50	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=50 Page: 41, (ClinPharm) 28, 50	no
CYP2E1 970	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28 Page: 41, (ClinPharm) 28, 50	no
CYP3A4/5 335	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28 Page: 41, (ClinPharm) 28, 50	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=41, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=50 Page: 41, (ClinPharm) 28, 50	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=79, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28 Page: 78-80, (ClinPharm) 28, 51	no
Kv1.3 32	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=32, https://pharmrev.aspetjournals.org/content/57/4/473.short Page: 32; Pharmacological Reviews December 2005, 57 (4) 473-508	weak [IC50 195 uM]
Kv1.5 41	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=33, https://pharmrev.aspetjournals.org/content/57/4/473.short Page: 33; Pharmacological Reviews December 2005, 57 (4) 473-508	weak [IC50 270 uM]

Drug as victim

Target	Modality	Activity
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 25, 38, 42	major
CYP1A1 349	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP1B1 92	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP2C18 138	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
CYP4A11 119	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=38 Page: (ClinPharm) 38, 42	minor
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=79, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=28 Page: 78-80, (ClinPharm) 28, 50-51	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250s000_PharmR.pdf#page=36, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022250Orig1s000ClinPharmR.pdf#page=36 Page: 34, 36, (ClinPharm) 36-37

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY20017	https://www.001chemical.com/chem/504-24-5
3B Scientific (Wuhan) Corp	3B4-3755	http://www.3bsc.com/index/pro_info.php?id=81309
AA Blocks	AA00395U	http://www.aablocks.com/goods/Goods/detail?id=AA00395U
AHH Chemical co.,ltd	MT-41399	http://www.ahhchemical.com/product/MT-41399.html
AK Scientific, Inc. (AKSCI)	65625	http://www.aksci.com/item_detail.php?cat=65625
AK Scientific, Inc. (AKSCI)	HTS004685	http://www.aksci.com/item_detail.php?cat=HTS004685
AZEPINE	AZ0001-0464	http://azepine.com/4-aminopyridine-1725.html
AbMole Bioscience	M5368	http://www.abmole.com/products/4-aminopyridine.html
Acadechem	ACDS-027426	http://www.acadechemical.com/product/102125
Aceschem	ACS010090	https://www.aceschem.com/catalog/504-24-5.html
Achemo Scientific Limited	AC-15123	http://www.achemo.com/search/?Keyword= 504-24-5
Achemtek	0104-010270	http://www.achemtek.com/504-24-5
Acorn PharmaTech	ACN-049544	http://www.acornpharmatech.com/
Acros Organics	AC104570010	https://www.fishersci.com/shop/products/4-aminopyridine-98-acros-organics-3/AC104570010
Acros Organics	AC104570050	https://www.fishersci.com/shop/products/4-aminopyridine-98-acros-organics/AC104570050
Acros Organics	AC104570250	https://www.fishersci.com/shop/products/4-aminopyridine-98-acros-organics/AC104570250
Acros Organics	AC104571000	https://www.fishersci.com/shop/products/4-aminopyridine-98-acros-organics/AC104571000
Alfa Aesar	A12405	https://www.alfa.com/en/catalog/A12405/
Allbio Pharm Co., Ltd	AD04545	http://www.allbiopharm.com/product/n/AD04545
Ambinter	Amb1933715	http://www.ambinter.com/reference/1933715
Ampyridine	AM10964	https://www.ampyridine.com/pyridine/504-24-5.html
Angene	AGN-PC-079T89	http://www.angenechemical.com/productshow/AGN-PC-079T89.html
Anward	ANW-75388	http://www.anward.com/pro_result/61839
ApexBio Technology	B3530	http://www.apexbt.com/4-aminopyridine-29428.html
Aromalake	LS20499	http://www.aromalake.com/4-Aminopyridine-p1961.html
Aronis	ARONIS25052	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=17946
AstaTech, Inc.	RB8003	http://www.astatechinc.com/CPSResult.php?CRNO=12856
Aurora Fine Chemicals LLC	A00.156.495	http://online.aurorafinechemicals.com/info?ID=A00.156.495
Aurora Fine Chemicals LLC	K02.104.088	http://online.aurorafinechemicals.com/info?ID=K02.104.088
Aurum Pharmatech LLC	M-6065	http://www.Aurumpharmatech.com/Product/ProductDetails/M_6065
Avantor Inc	BT219575-1KG	https://us.vwr.com/store/product/16902324/4-aminopyridine-98
Avantor Inc	BT219575-250G	https://us.vwr.com/store/product/16902324/4-aminopyridine-98
Avantor Inc	BT219575-50G	https://us.vwr.com/store/product/16902324/4-aminopyridine-98
Avantor Inc	200010-202	https://us.vwr.com/store/product/7513676/4-aminopyridine
Avantor Inc	TCA0414-100G	https://us.vwr.com/store/product/9982810/4-aminopyridine-99-0-by-gc-titration-analysis
BOC Sciences	45498-20-2	https://www.bocsci.com/fampridine-d4-cas-45498-20-2-item-404055.html
Beijing Acemol Technology	AMPD00207	http://www.acemol.com/products/PAMPD00207.shtml
BioCrick	BCC5267	http://www.biocrick.com/4-Aminopyridine-BCC5267.html
BioSynth	Q-200436	https://www.biosynth.com/en/products/chemical-intermediates/advanced-intermediates/products/Q-200436.html
Boerchem	BC227053	http://www.boerchem.com/?product_38268.html
BroadPharm	BP-21343	https://www.broadpharm.com/web/product.php?catalog=BP-21343
Calbiochem	165405	http://www.emdbiosciences.com/product/165405
Capot Chemical	1281	http://www.capotchem.com/en/1281.htm
Capot Chemical	PubChem1281	http://www.capotchem.com/en/1281.htm
Chem Scene	CS-2822	http://www.chemscene.com/504-24-5.html
ChemMol	1201333	http://www.chemmol.com/chemmol/1201333.html
ChemMol	44008026	http://www.chemmol.com/chemmol/44008026.html
ChemMol	49427550	http://www.chemmol.com/chemmol/49427550.html
ChemMol	99116275	http://www.chemmol.com/chemmol/99116275.html
ChemShuttle	132775	http://www.chemshuttle.com/catalogsearch/result/?q=504-24-5&cat=
Chemspace	CSSB00000211974	https://chem-space.com/CSSB00000211974
Clearsynth	CS-O-00258	https://www.clearsynth.com/en/CSO00258.html
DC Chemicals	DC31634	http://www.dcchemicals.com//product_show-4-aminopyridine.html
Debye Scientific	DB-028705	http://www.debyesci.com/DB-028705.html
EMD Millipore	165405	http://www.emdbiosciences.com/product/165405
Enamine	Z955123498	https://www.enaminestore.com/catalog/Z955123498
Finetech	FT-0665455	http://www.finetechnology-ind.com/prod/detail/pub/45498-20-2.html
FondChemical	FDB-1816	http://www.fondchemical.com/cpshow_cid_8_pid_1012.html
Glentham Life Sciences	GK4384	http://www.glentham.com/products/product/GK4384/
Hairui	HR1281	http://www.hairuichem.com/en/product/504-24-5.html
Hello Bio	HB1073	https://www.hellobio.com/4-aminopyridine.html
LGC Standards	DRE-C10222000	https://www.lgcstandards.com/US/en/p/DRE-C10222000
LGC Standards	MM3462.00	https://www.lgcstandards.com/US/en/p/MM3462.00
MIC Scientific	HC150041	http://www.michemical.com/mkdetail.php?id=520
Matrix Scientific	167614	https://www.matrixscientific.com/167614.html
MedChem Express	HY-B0604	https://www.medchemexpress.com/4-aminopyridine.html
Molcore	MC20017	https://www.molcore.com/product/504-24-5
MuseChem	I003792	https://www.musechem.com/product/I003792.html
Oakwood	47207	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=41069&ExtHyperLink=1
Otava	2825458	https://search.otavachemicals.com/#!/search?query=2825458&type=code&base=dbb
Parchem	31704	http://www.parchem.com/chemical-supplier-distributor/4-aminopyridine-021704.aspx
R&D Chemicals	A106	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=6446
Renno Tech	RP18049	http://www.rennotech.com/product_show.asp?id=23917
Sigma-Aldrich	275875_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/275875?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	A78403_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/a78403?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	36687_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/36687?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1162454_USP	https://www.sigmaaldrich.com/catalog/product/usp/1162454?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S011769	http://www.sinfoobiotech.com/product/1015167
Smolecule	S524966	http://www.smolecule.com/products/s524966
TCI (Tokyo Chemical Industry)	A0414	http://www.tcichemicals.com/eshop/en/us/commodity/A0414/index.html
THE BioTek	bt-266950	https://www.thebiotek.com/product/inhibitors/bt-266950
Tocris	940	https://www.tocris.com/products/4-aminopyridine_0940
Vesino Industrial Co Ltd	VP10051	http://www.vsnchem.com/goto/product/42616/
Vitas-M Laboratory	BBL009925	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL009925&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
VladaChem	VL140270	https://www.vladachem.com/product.php?products=504-24-5
VladaChem	VL165921	https://www.vladachem.com/product.php?products=504-24-5
Yuhao Chemical	CJ2909	http://www.chemyuhao.com/504-24-5.html
abcr GmbH	AB108862	http://www.abcr.com/shop/en/AB108862
eNovation Chemicals	D403252	http://www.enovationchem.com/productDetails.asp?productID=D403252
mcule	MCULE-6604546217	https://mcule.com/MCULE-6604546217/

PubMed

Title	Date	PubMed
Gene structures and expression profiles of three human KCND (Kv4) potassium channels mediating A-type currents I(TO) and I(SA).	2000 Mar 1	10729221
Treatment of the neuromuscular junction with 4-aminopyridine results in improved reinnervation following nerve injury in neonatal rats.	2001	11311807
Firing properties of identified superior laryngeal neurons in the nucleus ambiguus in the rat.	2001 Apr 27	11297809
Effects of phosphodiesterase inhibitors on hypoxic pulmonary vasoconstriction. Influence of K(+) channels and nitric oxide.	2001 Apr 6	11301069
A model for 4-aminopyridine action on K channels: similarities to tetraethylammonium ion action.	2001 Aug	11463633
Blockage of one class of potassium channel alters the effectiveness of halothane in a brain circuit of Drosophila.	2001 Feb	11159264
Theta-frequency bursting and resonance in cerebellar granule cells: experimental evidence and modeling of a slow k+-dependent mechanism.	2001 Feb 1	11157062
The effect of acidosis on the ECG of the rat heart.	2001 Jan	11429616
Three types of K(+) currents in murine osteocyte-like cells (MLO-Y4).	2001 Jan	11165940
Activation of potassium conductance by ophiopogonin-D in acutely dissociated rat paratracheal neurones.	2001 Jan	11159695
Phorbol ester-induced inhibition of potassium currents in rat sensory neurons requires voltage-dependent entry of calcium.	2001 Jan	11152736
Development and validation of a capillary electrophoresis assay for the determination of 3,4-diaminopyridine and 4-aminopyridine including related substances.	2001 Jan 12	11217039
K(ATP) channel blockers selectively interact with A(1)-adenosine receptor mediated modulation of acetylcholine release in the rat hippocampus.	2001 Jan 19	11166687
Diversity of K+ channels in circular smooth muscle of opossum lower esophageal sphincter.	2001 Jul	11478595
KT3.2 and KT3.3, two novel human two-pore K(+) channels closely related to TASK-1.	2001 Jul	11431495
Relaxation to authentic nitric oxide and SIN-1 in rat isolated mesenteric arteries: variable role for smooth muscle hyperpolarization.	2001 Jul	11429390
Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells.	2001 Jul	11401838
Gap junctions synchronize the firing of inhibitory interneurons in guinea pig hippocampus.	2001 Jul 13	11430896
Role of K+ -channels in homotaurine-induced analgesia.	2001 Jun	11468027
Potassium channels regulate tone in rat pulmonary veins.	2001 Jun	11350792
Mechanisms underlying presynaptic facilitatory effect of cyclothiazide at the calyx of Held of juvenile rats.	2001 Jun 1	11389202
Membrane resonance and subthreshold membrane oscillations in mesencephalic V neurons: participants in burst generation.	2001 Jun 1	11356860
Theoretical analysis of the molecular determinants responsible for the K(+) channel blocking by aminopyridines.	2001 Jun 15	11403883
Potassium channel blocker TEA prevents CA1 hippocampal injury following transient forebrain ischemia in adult rats.	2001 Jun 8	11376889
Effects of pituitary adenylate cyclase activating polypeptide on lumbosacral preganglionic neurons in the neonatal rat spinal cord.	2001 Mar 23	11259781
Sites and ionic mechanisms of hypoxic vasoconstriction in frog skin.	2001 May	11294748
Mobilization of calcium from intracellular stores, potentiation of neurotransmitter-induced calcium transients, and capacitative calcium entry by 4-aminopyridine.	2001 May 1	11312298

Patents

Sample Use Guides

In Vivo Use Guide

The maximum recommended dose of AMPYRA is one 10 mg tablet twice daily, taken with or without food, and should not be exceeded.

Route of Administration: Oral

In Vitro Use Guide

At DIV25, the differentiating cells were re-seeded to Matrigel coated 12-mm glass coverslips in densities of 400,000 cells per well. Media was replaced completely the next day by fresh maturation media. Media containing either 100 mM 4-Aminopyridine diluted in DMSO or the equivalent amount DMSO only was given to the cells 72 hours before the start of week 7 (DIV42) and lasted until the cells were analyzed during week 7. Half the media was replaced every third day. Final electrophysiological recordings of the treated vs. non-treated cells rigorously were taken in pairs of one treated and one nontreated coverslip within a time frame of 48 hours.

Name

Type

Language

DALFAMPRIDINE

Official Name

English

fampridine [INN]

Common Name

English

DALFAMPRIDINE [HSDB]

Common Name

English

FAMPRIDINE

Official Name

English

DALFAMPRIDINE [II]

Common Name

English

DALFAMPRIDINE [MI]

Common Name

English

4-AP

Common Name

English

FAMPRIDINE [JAN]

Common Name

English

FAMPRIDINE [MART.]

Common Name

English

DALFAMPRIDINE [ORANGE BOOK]

Common Name

English

AMPYRA

Brand Name

English

DALFAMPRIDINE [USAN]

Common Name

English

DALFAMPRIDINE [VANDF]

Common Name

English

PYRIDIN-4-AMINE

Systematic Name

English

Fampridine [WHO-DD]

Common Name

English

DALFAMPRIDINE [USP MONOGRAPH]

Common Name

English

FAMPRIDINE (4-AMINOPYRIDINE) [VANDF]

Common Name

English

DALFAMPRIDINE [USP-RS]

Common Name

English

4-PYRIDINAMINE

Systematic Name

English

FAMPRIDINE [VANDF]

Common Name

English

FAMPRIDINE [EMA EPAR]

Common Name

English

4-Aminopyridine

Systematic Name

English

EL-970

Code

English

NSC-15041

Code

English

FAMPYRA

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C93038